HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach July 8, 2025
Imfinzi approved in the EU for muscle-invasive bladder cancer based on data from NIAGARA Ph 3 trial July 8, 2025
Encouraging Survival Data in Patients with Metastatic CRC Previously Treated with Leronlimab Announced July 8, 2025
ZEGFROVY (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for NSCLC with EGFR Ex 20 Insertion Mutations July 8, 2025
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies July 8, 2025
Recruitment Initiated into Expanded Ph 2 Opaganib/Darolutamide Combo Study in Advanced Prostate Cancer July 8, 2025
Data from Ongoing Dose Escalation of BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma presented July 8, 2025
BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Ph 3 July 8, 2025
Presentation of positive Ph 1b data for givastomig, nivolumab, and mFOLFOX6 combo in 1L gastric cancer patients announced July 8, 2025
End of Ph 2 Meeting Granted by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma July 8, 2025
Austrian Regulatory Green Light Enables ADC Combination Testing and Ph 1 Site Expansion for ES2B-C001 July 8, 2025
NMPA clears application to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab in 1L metastatic HCC patients July 8, 2025
Submission of extension of indication application to EMA of AKEEGA with prednisone or prednisolone for mHSPC and HRR gene alterations announced July 8, 2025
Confirmatory Ph 3 trial of masitinib in metastatic CRPC authorized by FDA and EMA, with biomarker to target patients with less advanced metastatic disease July 8, 2025
FDA Clears IND Application for AXN-2510 for a Ph 1 Trial in Relapsed/Refractory Solid Tumors July 8, 2025
EC granted conditional marketing authorization for Ziihera® (zanidatamab) monotherapy for unresectable locally advanced or metastatic previously treated HER2-positive biliary tract cancer July 8, 2025
